Showing results (81-90 of 184) with videos related to

Sort By:
Pageof 19
Cancer Medicine|August 24, 2017
Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinomaHiroyuki Kitano, Yasuhiko Kitadai, Jun Teishima, et al.
Oncology Letters|July 12, 2017
A comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patientsKoichi Shoji, Jun Teishima, Tetsutaro Hayashi, et al.
Urologic Oncology|May 21, 2020
Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancerYohei Sekino, Xiangrui Han, Takashi Babasaki, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 15, 2026
Real-World Effectiveness and Safety of Pembrolizumab-Lenvatinib Versus Axitinib-Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective StudyKohei Kobatake, Keisuke Goto, Akira Fujita, et al.
Cell Reports|June 4, 2020
The Number of Transcription Factors at an Enhancer Determines Switch-like Gene ExpressionHiroki Michida, Hiroaki Imoto, Hisaaki Shinohara, et al.
Cancer Science|August 30, 2008
Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancerShinya Ohara, Naohide Oue, Akio Matsubara, et al.
Biomedicines|August 27, 2021
HOXB5 Overexpression Is Associated with Neuroendocrine Differentiation and Poor Prognosis in Prostate CancerYohei Sekino, Quoc Thang Pham, Kohei Kobatake, et al.
Urologic Oncology|March 7, 2020
Microtubule-associated protein tau (MAPT) is a promising independent prognostic marker and tumor suppressive protein in clear cell renal cell carcinomaXiangrui Han, Yohei Sekino, Takashi Babasaki, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 16, 2017
Impact of neutrophil-to-lymphocyte ratio on effects of targeted therapy for metastatic renal cell carcinoma patients with extrapulmonary metastasisJun Teishima, Shinya Ohara, Kousuke Sadahide, et al.
Histopathology|October 22, 2011
Desmocollin 2 is a new immunohistochemical marker indicative of squamous differentiation in urothelial carcinomaTetsutaro Hayashi, Kazuhiro Sentani, Naohide Oue, et al.
Pageof 19